Ding Xiaolong, Ma Yaozhen, Yin Meipan, Liu Tao, Jin Shuiling, Li Chunxia, Li Xiaobing, Zhang Chenchen, Zhou Gang, Wu Gang
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2024 Apr 26;14:1369829. doi: 10.3389/fonc.2024.1369829. eCollection 2024.
Obstruction is a common complication of advanced colorectal cancer. This study was aimed at investigating the safety, efficacy, and feasibility of transcatheter arterial perfusion chemotherapy combined with lipiodol chemoembolization for treating advanced colorectal cancer complicated by obstruction.
This retrospective analysis was conducted using clinical data of patients with advanced colorectal cancer who received arterial infusion chemotherapy combined with lipiodol chemoembolization treatment at our center. Treatment efficacy was evaluated in terms of obstruction-free survival and overall survival, and treatment complications were monitored.
Fifty-four patients with colorectal cancer complicated by obstruction were included. All patients successfully underwent transcatheter arterial infusion combined with lipiodol chemoembolization treatment. The average lipiodol dose administered was 2.62 ± 1.45 ml (0.5-5.5 ml). No serious complications such as perforation or tumor dissemination occurred. The clinical success rate was 83.3% (45/54). One month after treatment, the objective response rate (ORR) and disease control rate (DCR) were 66.67% and 88.9%, respectively. The median obstruction-free survival was 5.0 months. No serious adverse events occurred. As of the last follow-up, 6 patients survived, 44 died, and 4 were lost to follow-up.
Our findings revealed that transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization is safe and effective for treating advanced colorectal cancer complicated by obstruction. It may serve as a new treatment strategy for patients with advanced colorectal cancer complicated by obstruction.
肠梗阻是晚期结直肠癌的常见并发症。本研究旨在探讨经导管动脉灌注化疗联合碘油化疗栓塞治疗合并肠梗阻的晚期结直肠癌的安全性、有效性和可行性。
本回顾性分析采用了在我院中心接受动脉灌注化疗联合碘油化疗栓塞治疗的晚期结直肠癌患者的临床资料。从无梗阻生存期和总生存期方面评估治疗效果，并监测治疗并发症。
纳入54例合并肠梗阻的结直肠癌患者。所有患者均成功接受经导管动脉灌注联合碘油化疗栓塞治疗。碘油平均用量为2.62±1.45 ml（0.5 - 5.5 ml）。未发生穿孔或肿瘤播散等严重并发症。临床成功率为83.3%（45/54）。治疗1个月后，客观缓解率（ORR）和疾病控制率（DCR）分别为66.67%和88.9%。无梗阻生存期的中位数为5.0个月。未发生严重不良事件。截至末次随访，6例患者存活，44例死亡，4例失访。
我们的研究结果表明，经导管动脉灌注化疗联合碘油化疗栓塞治疗合并肠梗阻的晚期结直肠癌是安全有效的。它可能成为合并肠梗阻的晚期结直肠癌患者的一种新的治疗策略。
